|
A Phase 2 Multicenter Single Arm Clinical Trial of ABX-EGF Monotherapy in Subjects with Metastatic Colorectal Cancer Following Treatment with Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy Clinical Trials Information presented on Clinical Trials Search is not intended to be a substitute for qualified health advice, trips or treatment by using a genuine doctor. We aren't doctors. Always consult your mD on A Phase 2 Multicenter Single Arm Clinical Trial of ABX-EGF Monotherapy in Subjects with Metastatic Colorectal Cancer Following Treatment with Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. A Phase 2 Multicenter Single Arm Clinical Trial of ABX-EGF Monotherapy in Subjects with Metastatic Colorectal Cancer Following Treatment with Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy Clinical research trials and A Phase 2 Multicenter Single Arm Clinical Trial of ABX-EGF Monotherapy in Subjects with Metastatic Colorectal Cancer Following Treatment with Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy health trials take place in a lot of of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / projects is to answer specific human medical questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, like A Phase 2 Multicenter Single Arm Clinical Trial of ABX-EGF Monotherapy in Subjects with Metastatic Colorectal Cancer Following Treatment with Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy. A Phase 2 Multicenter Single Arm Clinical Trial of ABX-EGF Monotherapy in Subjects with Metastatic Colorectal Cancer Following Treatment with Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy Clinical Trials and other clinical trials allow for volunteers to have health treatment alternatives before they are available to the general public. Many times the test subjects obtain treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a A Phase 2 Multicenter Single Arm Clinical Trial of ABX-EGF Monotherapy in Subjects with Metastatic Colorectal Cancer Following Treatment with Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy clinical trial. Subjects oftentimes recieve the most effective healthcare possible for their A Phase 2 Multicenter Single Arm Clinical Trial of ABX-EGF Monotherapy in Subjects with Metastatic Colorectal Cancer Following Treatment with Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy condition. Hazards are a reality, however, and could include additional or frequent doctor visits, healthcare dangers (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Phase 2 Multicenter Single Arm Clinical Trial of ABX-EGF Monotherapy in Subjects with Metastatic Colorectal Cancer Following Treatment with Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy A Phase 2 Multicenter Single Arm Clinical Trial of ABX-EGF Monotherapy in Subjects with Metastatic Colorectal Cancer Following Treatment with Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy
A Phase 2 Multicenter Single Arm Clinical Trial of ABX-EGF Monotherapy in Subjects with Metastatic Colorectal Cancer Following Treatment with Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy
For Condition: Colorectal Cancer
Status: Recruiting
Sponsor(s): Amgen ,
Synopsis: The purpose of this study is to determine that ABX-EGF will have clinically meaningful anti-tumor activity in patients with metastatic colorectal cancer who have developed progressive disease or relapsed while on or after prior fluoropyrimidine, irinotecan and oxaliplatin chemotherapy.
Details:
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Pathologic diagnosis of colorectal adenocarcinoma (diagnostic tissue obtained by tissue biopsy) - Metastatic colorectal carcinoma - Eastern Cooperative Oncology Group of 0, 1 or 2 - Documented evidence of disease progression during, or following treatment, with fluoropyrimidine, irinotecan and oxaliplatin chemotherapy for metastatic colorectal cancer - Radiographic documentation of disease progression during or within 6 months following the most recent chemotherapy regimen is required - Bidimensionally measurable disease - Tumor expressing EGFr by immunohistochemistry - At least 2 but no more than 3 prior chemotherapy regimens for metastatic colorectal cancer - Adequate hematologic, renal and hepatic function Exclusion Criteria: - Symptomatic brain metastases requiring treatment - Patient with a history of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis - Use of systemic chemotherapy or radiotherapy within 30 days before enrollment - Prior epidermal growth factor receptor targeting agents - Prior anti-tumor therapies including prior experimental agents or approved anti-tumor small molecules and biologics of short (less than 1 week) serum half-life within 30 days before enrollment, or prior experimental or approved proteins within 3 months before enrollment
Total Enrollment:
Location and Contact Information:
Research Site *Recruiting*
Littleton, Colorado,
United States
Recruiting
Research Site *Recruiting*
Port St. Lucie, Florida,
United States
Recruiting
Research Site *Recruiting*
Robbinsdale, Minnesota,
United States
Recruiting
Research Site *Recruiting*
Santa Fe, New Mexico,
United States
Recruiting
Research Site *Recruiting*
Manhasset, New York,
United States
Recruiting
Research Site *Recruiting*
Houston, Texas,
United States
Recruiting
Research Site *Recruiting*
Loma Linda, California,
United States
Recruiting
Research Site *Recruiting*
Skokie, Illinois,
United States
Recruiting
Research Site *Recruiting*
Montgomery, Alabama,
United States
Recruiting
Research Site *Recruiting*
Norwich, Connecticut,
United States
Recruiting
Research Site *Recruiting*
Chicago, Illinois,
United States
Recruiting
Research Site *Recruiting*
Salt Lake City, Utah,
United States
Recruiting
Research Site *Recruiting*
Thornton, Colorado,
United States
Recruiting
Research Site *Recruiting*
Stanford, Connecticut,
United States
Recruiting
Research Site *Recruiting*
Washington D.C., District of Columbia,
United States
Recruiting
Research Site *Recruiting*
Mt. Holly, New Jersey,
United States
Recruiting
Research Site *Recruiting*
Colorado Springs, Colorado,
United States
Recruiting
Research Site *Recruiting*
Columbus, Ohio,
United States
Recruiting
Research Site *Recruiting*
Cleveland, Ohio,
United States
Recruiting
Research Site *Recruiting*
Seattle, Washington,
United States
Recruiting
Research Site *Recruiting*
Indianapolis, Indiana,
United States
Recruiting
Research Site *Recruiting*
Flint, Michigan,
United States
Recruiting
Research Site *Recruiting*
Nashville, Tennessee,
United States
Recruiting
Research Site *Recruiting*
Augusta, Georgia,
United States
Recruiting
Research Site *Recruiting*
Atlanta, Georgia,
United States
Recruiting
Research Site *Recruiting*
Harvey, Illinois,
United States
Recruiting
Research Site *Recruiting*
Aurora, Colorado,
United States
Recruiting
Research Site *Recruiting*
Orange Park, Florida,
United States
Recruiting
Research Site *Recruiting*
Philadelphia, Pennsylvania,
United States
Recruiting
Research Site *Recruiting*
Evanston, Illinois,
United States
Recruiting
Research Site *Recruiting*
Omaha, Nebraska,
United States
Recruiting
Research Site *Recruiting*
Canton, Ohio,
United States
Recruiting
Research Site *Recruiting*
Dallas, Texas,
United States
Recruiting
Research Site *Recruiting*
Jacksonville, Florida,
United States
Recruiting
Research Site *Recruiting*
Billings, Montana,
United States
Recruiting
Research Site *Recruiting*
Bronx, New York,
United States
Recruiting
Research Site *Recruiting*
Collierville, Tennessee,
United States
Recruiting
Research Site *Recruiting*
Richardson, Texas,
United States
Recruiting
Research Site *Recruiting*
Howell, New Jersey,
United States
Recruiting
Research Site *Recruiting*
Cranston, Rhode Island,
United States
Recruiting
Research Site *Recruiting*
Boulder, Colorado,
United States
Recruiting
Research Site *Recruiting*
Libertyville, Illinois,
United States
Recruiting
Research Site *Recruiting*
Denver, Colorado,
United States
Recruiting
Research Site *Recruiting*
New York City, New York,
United States
Recruiting
Research Site *Recruiting*
Charlotte, North Carolina,
United States
Recruiting
Research Site *Recruiting*
Chapel Hill, North Carolina,
United States
Recruiting
Research Site *Recruiting*
Miami, Florida,
United States
Recruiting
Research Site *Recruiting*
Madison, Wisconsin,
United States
Recruiting
Additional Information:
Study ID Numbers: 20030167;
Study Start Date:
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00083616
Other Colorectal Cancer Studies:
1. Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction
2. Photodynamic Therapy System for Patients with Refractory/Unresponsive Solid Tumors
3. Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer
4. Vaccination Against Melanoma and Other Cancers
5. Open-label randomized phase 3 study of capecitabine in combo with XELOX vs fluorouracil/leucovorin w/ oxaliplatin (FOLFOX4) as treatment for pts w/ metastatic colorectal cancer, who've received prior treatment w/ CPT-11 in combo w/ fluorouracil/leucovorin as first line therapy
Related Studies:
Other Colorectal Cancer Clinical Trials
Other Ohio Clinical Trials
Other Cleveland Clinical Trials
A Phase 2 Multicenter Single Arm Clinical Trial of ABX-EGF Monotherapy in Subjects with Metastatic Colorectal Cancer Following Treatment with Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy
|
|
|
|
|
|
|
|